First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

Inclusion Criteria: * ≥18 years of age * Treated with PD for at least 3 months prior to enrolment * Well-functioning peritoneal catheter and no peritoneal catheter replacement for at least a month prior to enrolment * No PD-related infection (exit-site infection, tunnel infection or peritonitis) less than 8 weeks prior to enrolment (counting from the day that the treatment has been finished). * Previous or current use of Extraneal® with no contra-indications * Capable of understanding the patient information sheet and informed consent form (ICF) and give informed consent * Willing and able to comply with all study procedures and attend all study visits Exclusion Criteria: * Patients who are unable to provide informed consent * Patients who are unable to comply with study procedures * Patients who received renal replacement therapy other than conventional PD less than 8 weeks prior to enrolment * Patients who participated in an intervention trial less than 8 weeks prior to enrolment or are currently participating in an intervention trial. Patients in an observational study without any interventions or in post-market surveillance do not need to be excluded. * Patients with a PD-related infection (exit-site infection, tunnel infection or peritonitis) less than 8 weeks prior to enrolment (counting from the day that the treatment has been finished) * Patients with peritoneal catheter dysfunction or mechanical issues less than one month prior to enrolment * Patients who have never used Extraneal® dialysis fluid or have a contra-indication for Extraneal®: a known allergy to cornstarch or icodextrin; maltose or isomaltose intolerance; glycogen storage disease * Patients with an incompatible PD connection to the device (e.g. Fresenius PD system) * Patients with haemoglobin concentrations \< 6.2 mmol/L (\< 10 g/dL) less than 8 weeks prior to enrolment * Patients with hyperkalemia (\> 6.0 mmol/L) or hyponatremia (\< 130 mmol/L) in the 8 weeks prior to enrolment * Patients with hypocalcemia (plasma total calcium concentration corrected for albumin \<2.20 mmol/L or ionized calcium \<1.15 mmol/L) or hypomagnesemia (plasma magnesium concentration \<0.70 mmol/L) in the 8 weeks prior to enrolment * Patients with any serious medical condition which in the opinion of the investigator, may adversely affect the safety of the participant and/or effectiveness of the study * Female patients who are either (planning to become) pregnant within the study period or breast feeding * Patients with a life expectancy \<3 months * Anticipated living donor kidney transplantation \<3 months